The CYP171A1 inhibitor abiraterone, which blocks androgen synthesis, was approved for advanced-stage prostate cancer, and the BRAF inhibitor vemurafenib was approved for metastatic melanoma with the BRAF V600E mutation. This evidence concerns the gene BRAF and prostate cancer.